Expression of ER beta in urinary urothelial carcinoma: pathological and clinical significance
| Project/Area Number |
26460412
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SASANO HIRONOBU 東北大学, 大学院医学系研究科, 教授 (50187142)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 膀胱尿路上皮癌 / ERβ / エストロゲン合成酵素 / 遊走能 / MMP11 / STS / EST |
|---|
| Outline of Final Research Achievements |
We demonstrated that ER beta and estrogen-producing/metabolizing enzymes were expressed in human urinary urothelial carcinoma, and ER beta might inhibit migration of the carcinoma cells as well as the expression level of MMP11 in the cells. On the other hand, we also confirmed that the expression levels of these enzymes were significantly and inversely correlated with pT stage. Therefore, we conclude that estrogen synthesized in situ could repress development of urinary urothelial carcinoma cells via ER beta, but the lower expression levels of these enzymes in advanced pT stage cases might result in decreased estrogen production and progression and invasion of carcinoma cells.
|
Report
(4 results)
Research Products
(3 results)
